Newstral
Patented Medicine Prices Review Board
- Oh, Canada: U.S. Patients Don't Want Your Health PoliciesForbes
- PMPRB releases 2022 Annual Report and March 2024 NEWSletterjdsupra.com
- Federal Court finds PMPRB reasonably concluded Galderma’s patent claiming 0.3% adapalene “pertained to” 0.1% adapalene DIFFERINjdsupra.com
- PMPRB publishes scoping paper for consultation on guidelines, and invites stakeholder feedbackjdsupra.com
- PMPRB news: Upcoming roundtable as first phase of new guidelines consultation, two new appointmentsjdsupra.com
- PMPRB adopts Amended Interim Guidance pending release of new guidelinesjdsupra.com
- New Vice Chairperson appointed, Meds Entry Watch 7th Ed. publishedjdsupra.com
- PMPRB publishes annual Meds Pipeline Monitor reportjdsupra.com
- Health minister accused of meddling in work of drug price review boardCBC
- House of Commons Standing Committee on Health meets for study of the PMPRBjdsupra.com
- Update on biosimilars in Canada – March 2023jdsupra.com
- Justin Trudeau’s former health minister slams his government for delay in lowering drug pricesthestar.com
- Why Justin Trudeau’s health minister is accused of caving to corporate intereststhestar.com
- New PMPRB Guidelines will not be implemented January 1, 2023jdsupra.com
- 2021 PMPRB Annual Reportjdsupra.com
- PMPRB finds ultra-rare drug PROCYSBI is excessively pricedjdsupra.com
- Draft revised PMPRB Guidelines released for comment by December 5, 2022jdsupra.com
- New PMPRB regulations registered, in force July 1, 2022, interim approach to pricing announcedjdsupra.com
- After a 5-year fight to lower drug prices, Ottawa's pledge quietly falls apartCBC
- PMPRB releases 2020 Annual Report and April 2022 NEWSletterjdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.